In fact, my guess is that cf33 has potentially not shown enough efficacy to be a commercial proposition, and the trial has thus slowed recruitment (sparse, and the no, updates for ages), seemingly akin to every other trial IMU has ever run. If anyone disagrees, please provide any evidence, as I would like to be wrong about this. Pick any trial and outcome in IMUs history.
So the focus seems to be on OnCar, with fingers crossed.
Azercel, I am 50/50 on due to the toxicity issues to overcome highlighted by Dr. Shah. How did imu buy it so cheaply?
GLTA.
IMU Price at posting:
5.5¢ Sentiment: None Disclosure: Held
